An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

Purpose:

To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.

Criteria:

Inclusion Criteria Patients must have the following: - Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP). - Dose-limiting intolerance to TMP / SMX and parenteral pentamidine. - Willingness and ability to give informed consent. Exclusion Criteria Co-existing Condition: Excluded: - Patients with a history of intolerance to 566C80. Patients with the following prior conditions are excluded: History of serious dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug. Required: - Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.

NCT ID:

NCT00001990

Primary Contact:

N/A

Backup Contact:

N/A

Location Contact:

Research Triangle Park, North Carolina 27709
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.